The rise of DOLs doesn’t mean pharma should upend KOL approach.
Read Roberts
Advertisement
Director, KOL Data Solutions, PRECISIONscientia
Articles by Read Roberts
Advertisement
Latest Updated Articles
Food for Thought: Make Room for Multiple OpinionsPublished: March 10th 2023 | Updated: February 13th 2025
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
4
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
5